HuGE Literature Finder
Records 1-30
|
Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA.
EBioMedicine 2020 Nov 62 103103. Dietz Steffen, Christopoulos Petros, Yuan Zhao, Angeles Arlou Kristina, Gu Lisa, Volckmar Anna-Lena, Ogrodnik Simon J, Janke Florian, Fratte Chiara Dalle, Zemojtel Tomasz, Schneider Marc A, Kazdal Daniel, Endris Volker, Meister Michael, Muley Thomas, Cecchin Erika, Reck Martin, Schlesner Matthias, Thomas Michael, Stenzinger Albrecht, Sültmann Holg |
|
ctDNA in neuroendocrine carcinoma of gastroenteropancreatic origin or of unknown primary: the CIRCAN-NEC pilot study.
Neuroendocrinology 2020 Oct . Gerard Laura, Garcia Jessica, Gauthier Arnaud, Lopez Jonathan, Durand Alice, Hervieu Valérie, Lemelin Annie, Chardon Laurence, Landel Verena, Gibert Benjamin, Lombard-Bohas Catherine, Payen Lea, Walter Thom |
|
Dynamic analysis of circulating tumor DNA to predict prognosis and monitor therapeutic response in metastatic relapsed cervical cancer.
International journal of cancer 2020 Oct . Tian Xiaoyuan, Ge Dongcen, Zhang Feng, Zhang Bocheng, Bai Wanting, Xu Xiaoying, Li Zongjuan, Cao Ying, Li Peiying, Zou Kun, Zou Liju |
|
Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial.
British journal of cancer 2020 Feb . Aparicio Thomas, Bennouna Jaafar, Le Malicot Karine, Boige Valérie, Taieb Julien, Bouché Olivier, Phelip Jean-Marc, François Eric, Borel Christian, Faroux Roger, Dahan Laetitia, Bachet Jean-Baptiste, Egreteau Joelle, Kaminsky Marie-Christine, Gornet Jean-Marc, Cojocarasu Oana, Gasmi Mohamed, Guerin-Meyer Véronique, Lepage Côme, Ghiringhelli François, |
|
Analysis of Molecular Pretreated Tumor Profiles as Predictive Biomarkers of Therapeutic Response and Survival Outcomes after Neoadjuvant Therapy for Rectal Cancer in Moroccan Population.
Disease markers 2020 2020 8459303. El Otmani Ihsane, El Agy Fatima, El Baradai Sanae, Bouguenouch Laila, Lahmidani Nada, El Abkari Mohammed, Benajah Dafr Allah, Toughrai Imane, El Bouhaddouti Hicham, Mouaqit Ouadii, Ibn Majdoub Hassani Karim, Mazaz Khalid, Benjelloun El Bachir, Ousadden Abdelmalek, El Rhazi Karima, Bouhafa Touria, Benbrahim Zineb, Ouldim Karim, Ibrahimi Sidi Adil, Ait Taleb Khalid, Chbani Lai |
|
Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis.
Cancer medicine 2019 Dec . Bylsma Lauren C, Gillezeau Christina, Garawin Tamer A, Kelsh Michael A, Fryzek Jon P, Sangaré Laura, Lowe Kimberly |
|
TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer.
Clinical genitourinary cancer 2019 Nov . Chapman Lynne, Ledet Elisa M, Barata Pedro C, Cotogno Patrick, Manogue Charlotte, Moses Marcus, Christensen Bryce R, Steinwald Peter, Ranasinghe Lahiru, Layton Jodi L, Lewis Brian E, Sartor Oliv |
|
Circulating tumor cell free DNA from plasma and urine in the clinical management of colorectal cancer.
Cancer biomarkers : section A of Disease markers 2019 Oct . Yu Haiying, Han Lan, Yuan Jia, Sun Yiny |
|
BRAF mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastases.
The British journal of surgery 2019 Jun . Bachet J-B, Moreno-Lopez N, Vigano L, Marchese U, Gelli M, Raoux L, Truant S, Laurent C, Herrero A, Le Roy B, Deguelte Lardiere S, Passot G, Hautefeuille V, De La Fouchardiere C, Artru P, Ameto T, Mabrut J Y, Schwarz L, Rousseau B, Lepère C, Coriat R, Brouquet A, Sa Cunha A, Benoist |
|
BRAF V600E Mutation: A Significant Biomarker for Prediction of Disease Relapse in Pediatric Langerhans Cell Histiocytosis.
Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society 2019 May 1093526619847859. Ozer Erdener, Sevinc Akin, Ince Dilek, Yuzuguldu Resmiye, Olgun N |
|
Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.
Annals of oncology : official journal of the European Society for Medical Oncology 2019 May 30 (5): 796-803. Santos C, Azuara D, Viéitez J M, Páez D, Falcó E, Élez E, López-López C, Valladares M, Robles-Díaz L, García-Alfonso P, Bugés C, Durán G, Salud A, Navarro V, Capellá G, Aranda E, Salazar |
|
Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.
Annals of oncology : official journal of the European Society for Medical Oncology 2019 Mar . Santos C, Azuara D, Viéitez J M, Páez D, Falcó E, Élez E, López-López C, Valladares M, Robles-Díaz L, García-Alfonso P, Bugés C, Durán G, Salud A, Navarro V, Capellá G, Salazar R, Aranda |
|
TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma.
Endocrine 2018 Jun . Penna Gustavo C, Pestana Ana, Cameselle José Manuel, Momesso Denise, de Andrade Fernanda Accioly, Vidal Ana Paula Aguiar, Araujo Junior Mario Lucio, Melo Miguel, Fernandes Priscila Valverde, Corbo Rossana, Vaisman Mario, Sobrinho-Simões Manuel, Soares Paula, Vaisman Fernan |
|
The genetic landscape of ganglioglioma.
Acta neuropathologica communications 2018 Jun 6 (1): 47. Pekmezci Melike, Villanueva-Meyer Javier E, Goode Benjamin, Van Ziffle Jessica, Onodera Courtney, Grenert James P, Bastian Boris C, Chamyan Gabriel, Maher Ossama M, Khatib Ziad, Kleinschmidt-DeMasters Bette K, Samuel David, Mueller Sabine, Banerjee Anuradha, Clarke Jennifer L, Cooney Tabitha, Torkildson Joseph, Gupta Nalin, Theodosopoulos Philip, Chang Edward F, Berger Mitchel, Bollen Andrew W, Perry Arie, Tihan Tarik, Solomon David |
|
Frequency of MAP2K1, TP53, and U2AF1 Mutations in BRAF-mutated Langerhans Cell Histiocytosis: Further Characterizing the Genomic Landscape of LCH.
The American journal of surgical pathology 2018 Apr . McGinnis Lisa M, Nybakken Grant, Ma Lisa, Arber Daniel |
|
Detection of EGFR, KRAS and BRAF mutations in metastatic cells from cerebrospinal fluid.
Clinical chemistry and laboratory medicine 2018 04 56 (5): 748-753. Frankel Diane, Nanni-Metellus Isabelle, Robaglia-Schlupp Andrée, Tomasini Pascale, Guinde Julien, Barlesi Fabrice, Astoul Philippe, Ouafik L'Houcine, Amatore Florent, Secq Véronique, Kaspi Elise, Roll Patri |
|
Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer.
Clinical colorectal cancer 2018 09 17 (3): 206-214. Kim Tae Won, Elme Anneli, Park Joon Oh, Udrea Anghel Adrian, Kim Sun Young, Ahn Joong Bae, Valencia Ricardo Villalobos, Krishnan Srinivasan, Manojlovic Nebojsa, Guan Xuesong, Lofton-Day Catherine, Jung A Scott, Vrdoljak Edua |
|
Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer.
World journal of gastroenterology 2017 Aug 23 (32): 5913-5924. Ntavatzikos Anastasios, Spathis Aris, Patapis Paul, Machairas Nikolaos, Peros George, Konstantoudakis Stefanos, Leventakou Danai, Panayiotides Ioannis G, Karakitsos Petros, Koumarianou An |
|
Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
BMC cancer 2017 Aug 17 (1): 536. Heppt Markus V, Siepmann Timo, Engel Jutta, Schubert-Fritschle Gabriele, Eckel Renate, Mirlach Laura, Kirchner Thomas, Jung Andreas, Gesierich Anja, Ruzicka Thomas, Flaig Michael J, Berking Caro |
|
Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Jul 35 (20): 2279-2287. Petty Russell D, Dahle-Smith Asa, Stevenson David A J, Osborne Aileen, Massie Doreen, Clark Caroline, Murray Graeme I, Dutton Susan J, Roberts Corran, Chong Irene Y, Mansoor Wasat, Thompson Joyce, Harrison Mark, Chatterjee Anirban, Falk Stephen J, Elyan Sean, Garcia-Alonso Angel, Fyfe David Walter, Wadsley Jonathan, Chau Ian, Ferry David R, Miedzybrodzka Zos |
|
Molecular Alterations in Patients with Pulmonary Adenocarcinoma Presenting with Malignant Pleural Effusion at the First Diagnosis.
Acta cytologica 2017 May . Rodriguez Erika F, Shabihkhani Maryam, Carter Jamal, Maleki Zah |
|
Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: a phase II study.
Cancer science 2017 Mar . Yamazaki Naoya, Kiyohara Yoshio, Uhara Hisashi, Uehara Jiro, Fujimoto Manabu, Takenouchi Tatsuya, Otsuka Masaki, Uchi Hiroshi, Ihn Hironobu, Minami Hirono |
|
Hobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma.
Oncotarget 2017 Mar 8 (13): 22023-22033. Teng Lianghong, Deng Wanglong, Lu Junliang, Zhang Jing, Ren Xinyu, Duan Huanli, Chuai Shannon, Duan Feidie, Gao Wei, Lu Tao, Wu Huanwen, Liang Zhiyo |
|
Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).
Gynecologic oncology 2017 Jan . Spreafico A, Oza A M, Clarke B A, Mackay H J, Shaw P, Butler M, Dhani N C, Lheureux S, Wilson M K, Welch S, Zhang T, Yu C, Stockley T, Siu L L, Kamel-Reid S, Bedard P |
|
Coexistence of KRAS and BRAF Mutations in Colorectal Cancer: A Case Report Supporting The Concept of Tumoral Heterogeneity.
Cell journal 2017 19 (Suppl 1): 113-117. Larki Pegah, Gharib Ehsan, Yaghoob Taleghani Mohammad, Khorshidi Fatemeh, Nazemalhosseini-Mojarad Ehsan, Asadzadeh Aghdaei Ham |
|
Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
BMC cancer 2017 01 17 (1): 38. Nakayama Izuma, Shinozaki Eiji, Matsushima Tomohiro, Wakatsuki Takeru, Ogura Mariko, Ichimura Takashi, Ozaka Masato, Takahari Daisuke, Suenaga Mitsukuni, Chin Keisho, Mizunuma Nobuyuki, Yamaguchi Kens |
|
Telomere shortening in non-tumorous and tumor mucosa is independently related to colorectal carcinogenesis in precancerous lesions.
International journal of molecular epidemiology and genetics 2017 8 (5): 53-58. Park Won-Jin, Bae Sung Uk, Heo Yu-Ran, Jung Soo-Jung, Lee Jae- |
|
Clinicopathological features and clinical outcomes associated with TP53 and BRAF(N)(on-)(V)(600) mutations in cutaneous melanoma patients.
Cancer 2016 Dec . Kim Dae Won, Haydu Lauren E, Joon Aron Y, Bassett Roland L, Siroy Alan E, Tetzlaff Michael T, Routbort Mark J, Amaria Rodabe N, Wargo Jennifer A, McQuade Jennifer L, Kemnade Jan, Hwu Patrick, Woodman Scott E, Roszik Jason, Kim Kevin B, Gershenwald Jeffrey E, Lazar Alexander J, Davies Michael |
|
Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
BMC cancer 2016 Nov 16 (1): 864. Ko Ryo, Kenmotsu Hirotsugu, Serizawa Masakuni, Koh Yasuhiro, Wakuda Kazushige, Ono Akira, Taira Tetsuhiko, Naito Tateaki, Murakami Haruyasu, Isaka Mitsuhiro, Endo Masahiro, Nakajima Takashi, Ohde Yasuhisa, Yamamoto Nobuyuki, Takahashi Kazuhisa, Takahashi Toshia |
|
Evaluation of gene mutations beyond KRAS as predictive biomarkers of response to panitumumab in a randomized, phase III monotherapy study of metastatic colorectal cancer (mCRC).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 May 29 (15_suppl): 3530. Oliner K, Peeters M, Siena S, Van Cutsem E, Huang J, Humblet Y, Van Laethem J, Andre T, Wiezorek J S, Patterson S |
- Page last reviewed:Oct 1, 2020
- Page last updated:Nov 23, 2020
- Content source: